PRIMARY STUDY
Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death
Key Findings: TRPV1 (and potentially CB2) antagonism via NADA for example may present novel treatment potential for patients with immune dysfunction in end-stage kidney disease.
Type of Study: Laboratory Study
Study Result: Positive
Study Location(s): Australia
Year of Pub: 2009
Cannabinoids Studied: N-Arachidonoyl Dopamine (NADA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB2, TRPV1
